Related Experiment Video

Updated: Apr 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure

Filip Y Fisker1, Daniela Grimm1, Markus Wehland2

  • 1Department of Biomedicine, Pharmacology, Aarhus University, Aarhus, Denmark.

Basic & Clinical Pharmacology & Toxicology
|March 4, 2015
PubMed

Insights

Third-generation beta-adrenoceptor antagonists (BAAs) offer unique vasodilating and antioxidant properties beyond receptor blockade. These advanced drugs show promise for treating hypertension and heart failure, with potential benefits for cardiovascular health.

Area of Science:

  • Cardiovascular Pharmacology
  • Clinical Hypertension
  • Heart Failure Management

Background:

  • Beta-adrenoceptor antagonists (BAAs) have been a cornerstone of hypertensive treatment for 40 years, reducing mortality and morbidity.
  • Significant pharmacological variations exist among BAAs, including lipophilicity, receptor selectivity, and additional cardiovascular effects.
  • Third-generation BAAs exhibit distinct properties, such as nitric oxide-mediated vasodilation and antioxidant effects, beyond their primary receptor-blocking actions.

Purpose of the Study:

  • To review the effects of third-generation BAAs on the vasculature in patients with hypertension and chronic heart failure (CHF).
  • To highlight the unique pharmacological properties of newer BAAs, including nebivolol and carvedilol.
  • To discuss the potential applications of these advanced BAAs in various patient populations, including those with CHF and post-cardiovascular events.

Main Methods:

  • Review of existing literature on third-generation beta-adrenoceptor antagonists.
  • Analysis of pharmacological properties: lipophilicity, receptor selectivity, and additional vascular effects.
  • Discussion of clinical implications for hypertension, chronic heart failure, and cardiovascular event management.

Main Results:

  • Nebivolol demonstrates nitric oxide-mediated vasodilation, improving arterial rigidity.
  • Carvedilol exhibits antioxidant and antiproliferative effects beneficial in chronic heart failure (CHF).
  • Third-generation BAAs possess unique properties that may enhance their therapeutic value beyond traditional beta-blockade.

Conclusions:

  • The full therapeutic potential of third-generation BAAs in hypertension and CHF remains to be fully recognized.
  • Distinct pharmacological profiles of newer BAAs, such as nebivolol and carvedilol, offer advantages for specific patient groups.
  • Further research and clinical application of third-generation BAAs are warranted to optimize cardiovascular disease management.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

12.2K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K